Home-based breathing exercises to reduce side effects in breast cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of a 12-week home-based respiratory muscle training (RMT) program for patients undergoing treatment for breast cancer. The program aims to minimize heart and lung-related side effects caused by chemotherapy, which can negatively impact quality of life. Participants will be randomized into two groups, receiving either lower or higher resistance RMT using a specialized device. The study will assess the feasibility of the program and its impact on cardiac function, exercise performance, and patient-reported symptoms.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Able and willing to provide written informed consent
* Age \>= 21 years old
* Diagnosed with solid tumor (e.g., head and neck, thoracic, or breast cancer)
* Scheduled to receive at least one dose of chemotherapy or immunotherapy or radiation
* Treated at Roswell Park Comprehensive Cancer Center

Exclusion Criteria:

* Presence of oral mucosal disease including oral mucositis, or oral candidiasis detected at baseline
* Have uncontrolled intercurrent illness including, but not limited to, ongoing or active respiratory infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, heart failure or psychiatric illness/social situations that would limit compliance with study requirements
* Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study intervention

Where it's running

• Roswell Park Cancer Institute
  Buffalo, New York, United States Recruiting

Study contacts

• Principal investigator: Ellis Levine, MD — Roswell Park Cancer Institute
• Study coordinator: Ask Rpci
• Email: askrpci@roswellpark.org
• Phone: 1-877-275-7724

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Does the time of day for PD-1/PD-L1 therapy affect response in NSCLC and HNSCC

  In people with advanced NSCLC or resectable head and neck cancer, this study tests whether receiving PD-1/PD-L1 therapy in the morning versus the afternoon changes treatment outcomes.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07630168

• Blood extracellular vesicles to detect chemotherapy-related nerve damage.

  We will test whether tiny blood particles called extracellular vesicles can predict who will develop chemotherapy-induced peripheral neuropathy in adults receiving taxane, platinum, or antimitotic chemotherapy.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07558447

• High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)

  This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07524114

• Riluzole to prevent thinking and memory problems during chemotherapy

  This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07447050

• Collecting blood and leftover tumor tissue to test molecular residual disease (MRD) detection

  This project will test whether blood and leftover tumor tissue from adults with certain solid tumors can be used with Natera's MRD blood tests to find tiny amounts of cancer (ctDNA) after treatment.

  Recruiting Natera, Inc. · Austin, Texas · NCT07318051

• Dual Energy CT to Delineate Tumors and Organs at Risk in Radiotherapy

  This study tests whether dual-energy CT can delineate tumors and nearby critical tissues as well as MRI for patients needing radiotherapy.

  Recruiting at 2 sites Aalborg University Hospital · Aalborg and 2 other locations · NCT07185958

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.